The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
Introduction: Treatment patterns in stage III NSCLC can vary considerably between countries. The PACIFIC trial reported improvements in progression-free and overall survival with adjuvant durvalumab after concurrent chemoradiotherapy (CCRT). We studied treatment decision-making by three Dutch regional thoracic multidisciplinary tumor boards between 2015 and 2019, to identify changes in practice when adjuvant durvalumab became available. Methods: Details of patients presenting with stage III NSCLC were retrospectively collected. Both CCRT and multimodality schemes incorporating planned surgery... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100195- (2021) |
Verlag/Hrsg.: |
Elsevier
|
Schlagwörter: | Non–small cell lung cancer (NSCLC) / Stage III / Multidisciplinary tumor board (MDT) / Patterns of care / Immunotherapy / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26626854 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1016/j.jtocrr.2021.100195 |